A case of cyclophosphamide-induced posterior reversible encephalopathy syndrome: Is it dose-related side effect?

Theeb Osama Sulaiman, Ahmed K A Yasin, Abdellatif Ismail

Keywords: Antineutrophil cytoplasmic antibody, Cyclophosphamide, Posterior reversible encephalopathy syndrome, Renalpulmonary disease

DOI: 10.32677/yjm.v1i2.3684

DOI URL: https://doi.org/10.32677/yjm.v1i2.3684

Publish Date: 29-03-2025

Pages: 103 - 107

Views: 4

Downloads: 9

Author Affiliation:

From ¹Consultant,

²Resident, Department of Medicine, Hamad General Hospital, Doha, Qatar

Abstract

We reported a case of cyclophosphamide (CYP)-induced posterior reversible encephalopathy syndrome (PRES) in a 26-year-old previously healthy male patient who was presented to the emergency department with a history of fever, shortness of breath, and hemoptysis. After extensive investigations, including bronchoscopy and autoimmune screening, he was diagnosed with renalpulmonary syndrome. The diagnosis of CYP-related PRES was based on the development of neurological clinical picture supported by magnetic resonance imaging findings. The dose of CYP was decreased to 75 mg/day, and the patient’s symptoms improved after 3 days.